Sugammadex dosing based on ideal or actual body weight in underweight patients.

Sugammadex dosing based on ideal or actual body weight in underweight patients - Sugammadex dosing based on ideal or actual body weight in underweight patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040550

Enrollment

Registered

2021-05-27

Start date

2020-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Underweight

Interventions

doses based on actual body weight doses based on ideal body weight

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: BMI below 18.5 ASA-PS= 1-3

Exclusion criteria

Exclusion criteria: patient who is allergic to muscle relaxants patient who has neuromuscular diseases patient who has moderate to severe liver function failure

Design outcomes

Primary

Measure	Time frame
Time from sugammadex administration to normarized TOFR=100%.	—

Countries

Japan

Contacts

Public ContactHajime Iwasaki

Nihon University School of Medicine Department of Anesthesiology

iwasaki.hajime@nihon-u.ac.jp+81-3-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026